Nader Sanai, MD | Barrow Neurological ...

Dr. Nader Sanai, MD

Claim this profile

St. Joseph's Hospital and Medical Center

Expert in Brain Tumor
Expert in Glioblastoma
16 reported clinical trials
21 drugs studied

Area of expertise

1Brain Tumor
Global Leader
Nader Sanai, MD has run 11 trials for Brain Tumor. Some of their research focus areas include:
RB
Stage III
Stage IV
2Glioblastoma
Global Leader
Nader Sanai, MD has run 11 trials for Glioblastoma. Some of their research focus areas include:
RB
IDH positive
p16

Affiliated Hospitals

Image of trial facility.
St. Joseph's Hospital And Medical Center
Image of trial facility.
Ivy Brain Tumor Center

Clinical Trials Nader Sanai, MD is currently running

Image of trial facility.

Abemaciclib

for Meningioma

This study is being done to learn about how an investigational drug called abemaciclib works in treating patients with a newly-diagnosed grade 3 meningioma. Abemaciclib is a drug that is approved by the FDA, but not for brain tumors. Participants who consent to the trial will have surgical tissue collected from the planned surgical resection and tested. If the tissue shows positive results for RB cells and participants are qualified, they will be enrolled and receive study treatment two to five weeks after completing standard-of-care radiation therapy. This is a randomized clinical trial which means that participants will be randomly assigned to a treatment based on chance, like a flip of a coin. Neither the participant nor the researcher chooses the assigned group. Randomization will help the researchers study how the drug works by comparing the difference between the study drug and the placebo and how they work in treating brain tumors. This is a double-blinded study, which means that neither the participant nor the study team will know which treatment the participant is receiving.
Recruiting0 awards Phase 212 criteria
Image of trial facility.

BDTX-1535

for Brain Tumor

This study will administer the investigational drug, BDTX-1535 to eligible patients with recurrent high-grade glioma (HGG) and newly-diagnosed glioblastoma (nGBM). BDTX-1535 was designed to block a growth signal important to some cancers. BDTX-1535 is being tested in this study to see if it can be given safely to people who have tumors that can be dependent on that growth signal because of changes in a protein called EGFR. These gene changes are called amplifications, mutations, fusions or alterations and are found only in the tumors. The study design includes a Phase 0 component with PK/PD-trigger for participant enrollment into an Expansion Phase 1 component. The primary objective of the Phase 0 component is to evaluate the PK endpoints of BDTX-1535. The primary objective of the Phase 1 component is to establish the safe dose of BDTX-1535 to be used in participants with a specified treatment regimen, three of which include standard of care radiotherapy for nGBM participants.
Recruiting1 award Phase < 16 criteria

More about Nader Sanai, MD

Clinical Trial Related4 years of experience running clinical trials · Led 16 trials as a Principal Investigator · 7 Active Clinical Trials
Treatments Nader Sanai, MD has experience with
  • Abemaciclib
  • Radiation Therapy
  • Ribociclib
  • SONALA-001 And Exablate 4000 Type 2
  • MR-Guided Focused Ultrasound Device (MRgFUS)
  • SONALA-001(ALA) And MR-Guided Focused Ultrasound Device (MRgFUS)

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Nader Sanai, MD specialize in?
Is Nader Sanai, MD currently recruiting for clinical trials?
Are there any treatments that Nader Sanai, MD has studied deeply?
What is the best way to schedule an appointment with Nader Sanai, MD?
What is the office address of Nader Sanai, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security